Theriva Biologics Inc Share Price Today: Live Updates & Key Insights

Theriva Biologics Inc share price today is $0.1937, up 4.36%. The stock opened at $0.1856 against the previous close of $0.1856, with an intraday high of $0.1937 and low of $0.1837.

Theriva Biologics Inc Share Price Chart

Theriva Biologics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Theriva Biologics Inc Share Price Performance

$0.1937 0.0436(4.36%) TOVX at 23 Mar 2026 03:32 PM Biotechnology
Lowest Today 0.1837
Highest Today 0.1937
Today’s Open 0.1856
Prev. Close 0.1856
52 Week High 1.50
52 Week Low 0.16
Day’s Range: Low 0.1837 High 0.1937
52-Week Range: Low 0.16 High 1.50
1 day return -
1 Week return -2.3
1 month return +3.2
3 month return -1.63
6 month return -53.55
1 year return -83.17
3 year return -72.56
5 year return -97.56
10 year return -

Theriva Biologics Inc Institutional Holdings

Theriva Biologics Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Theriva Biologics Inc Fundamentals

Market Cap 6.38 M

PB Ratio 0.5779

PE Ratio 0.0868

Enterprise Value -1.54 M

Total Assets 38.24 M

Volume 1839115

Theriva Biologics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-19309000 -19.3M, FY22:-19685000 -19.7M, FY21:-14174000 -14.2M, FY20:-9999000 -10.0M, FY19:-15020000 -15.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-27000 -0.0M, Q1/2025:-26000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-38000 -0.0M

Quarterly Net worth Q3/2025:-4361000 -4.4M, Q2/2025:-13058000 -13.1M, Q1/2025:-4324000 -4.3M, Q3/2024:-7726000 -7.7M, Q2/2024:-8316000 -8.3M

About Theriva Biologics Inc & investment objective

Company Information Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Organisation Biotechnology

Employees 15

Industry Biotechnology

CEO Mr. Steven A. Shallcross CPA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Theriva Biologics Inc FAQs

What is the share price of Theriva Biologics Inc today?

The current share price of Theriva Biologics Inc is $0.1937.

Can I buy Theriva Biologics Inc shares in India?

Yes, Indian investors can buy Theriva Biologics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Theriva Biologics Inc shares in India?

You can easily invest in Theriva Biologics Inc shares from India by:

Can I buy fractional shares of Theriva Biologics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Theriva Biologics Inc?

Theriva Biologics Inc has a market cap of $6.38 M.

In which sector does Theriva Biologics Inc belong?

Theriva Biologics Inc operates in the Biotechnology sector.

What documents are required to invest in Theriva Biologics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Theriva Biologics Inc?

The PE ratio of Theriva Biologics Inc is 0.09 and the PB ratio is 0.58.